Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.6K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.6K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

1.5K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
1.5K
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

5
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
5
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

1.2K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.2K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

3.3K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heart Disease Mortality in Cancer Survivors: A Population-Based Study in Japan.

Journal of the American Heart Associationยท2023
Same author

RGMa collapses the neuronal actin barrier against disease-implicated protein and exacerbates ALS.

Science advancesยท2023
Same author

Analysis of gut microbiome, host genetics, and plasma metabolites reveals gut microbiome-host interactions in the Japanese population.

Cell reportsยท2023
Same author

Comparison of surgical outcomes between iStent inject W implantation and microhook ab interno trabeculotomy in combination with phacoemulsification in primary open-angle glaucoma patients.

Frontiers in medicineยท2023
Same author

Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.

Neurology and therapyยท2023
Same author

Extracellular high molecular weight ฮฑ-synuclein oligomers induce cell death by disrupting the plasma membrane.

NPJ Parkinson's diseaseยท2023

Related Experiment Video

Updated: Apr 19, 2026

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

16.1K

[Therapeutic development in myotonic dystrophy].

Masanori P Takahashi1, Masayuki Nakamori, Hideki Mochizuki

  • 1Department of Neurology, Osaka University Graduate School of Medicine.

Rinsho Shinkeigaku = Clinical Neurology
|December 19, 2014
PubMed
Summary

Myotonic dystrophy (DM) is a genetic disorder caused by expanded RNA repeats. New therapies, including antisense oligonucleotides (ASOs), show promise, but patient identification and standardized care are crucial for clinical trials.

More Related Videos

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells
06:20

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Published on: May 7, 2020

7.5K
Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

7.4K

Related Experiment Videos

Last Updated: Apr 19, 2026

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

16.1K
Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells
06:20

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Published on: May 7, 2020

7.5K
Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

7.4K

Area of Science:

  • Genetics
  • Molecular Biology
  • Neurology

Context:

  • Myotonic dystrophy (DM) is the most prevalent adult muscular dystrophy.
  • It stems from expanded repeat sequences in untranslated gene regions.
  • Disease pathology involves RNA-mediated sequestration of splicing factors, leading to splicing misregulation.

Purpose:

  • To review current understanding of DM pathogenesis.
  • To discuss emerging therapeutic strategies targeting toxic RNA.
  • To highlight challenges in clinical trial implementation and patient management.

Summary:

  • Therapeutic strategies include antisense oligonucleotides (ASOs) for missplicing correction, RNA toxicity neutralization, and toxic RNA degradation.
  • ASOs targeting toxic RNA have shown efficacy in preclinical models, with a clinical trial now underway.
  • Challenges include patient identification for clinical trials and establishing standardized management protocols, particularly in Japan.

Impact:

  • Advancements in understanding DM mechanisms are driving novel therapeutic development.
  • Antisense oligonucleotide therapies show significant potential for treating DM.
  • A national DM registry is anticipated to aid patient identification and improve disease management.